Table of Contents
Chemotherapy Research and Practice
Volume 2016 (2016), Article ID 3439707, 5 pages
http://dx.doi.org/10.1155/2016/3439707
Clinical Study

The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India

1Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India
2Department of Community Health, St. John’s Medical College, Bangalore 560034, India

Received 29 September 2015; Revised 12 December 2015; Accepted 21 December 2015

Academic Editor: Kazuo Tamura

Copyright © 2016 Govind Babu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Govind Babu, Smitha Carol Saldanha, Lakshmaiah Kuntegowdanahalli Chinnagiriyappa, et al., “The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India,” Chemotherapy Research and Practice, vol. 2016, Article ID 3439707, 5 pages, 2016. doi:10.1155/2016/3439707